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methods with different breakpoints are in use. In a comparison
between MGIT and Middlebrook 7H10 medium of seven ﬁrst- and
second-line drugs, including 133 MIC determinations of 15 WT
isolates, we found an agreement of 91.7% within ± one MIC
dilution step. The results conﬁrm the agreement in MIC testing
between 7H10 and MGIT and indicate that breakpoints could be
harmonized in order to avoid misclassiﬁcation.
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p://dx.doi.org/10.1016/j.cmi.2014.08.021IntroductionFor Mycobacterium tuberculosis, the currently used clinical
breakpoints for drug susceptibility testing (DST)—critical
concentrations—are mostly based on consensus from the
1960s. This deﬁnition of clinical breakpoint is the drug con-
centration that inhibits 95% of susceptible strains but not
strains that are cultured from patients not responding to
therapy [1]. Several multicenter studies have been performed
to transfer the critical concentrations initially established in
Löwenstein-Jensen media to modern liquid and solid media
such as BACTEC 960 MGIT (MGIT) and Middlebrook 7H10
(7H10) by using a previous method as the reference [2,3]. In
those studies, no investigation of wild-type (WT) MIC dis-
tributions or large-scale direct comparisons of MICs between
methods were included. This strategy that does not take WT
distributions into account for the DST methods used today
has, to some extent, contributed to a poor reproducibility
and agreement for drugs such as ethambutol and for strains
with MICs close to both the epidemiological cut off (ECOFF)
and the critical concentration [4]. For other bacterial patho-
gens, susceptibility breakpoints are established by a combi-
nation of clinical outcome data, pharmacokinetic and
pharmacodynamic as well as WT distributions, according to
the standards of the European Committee on Antimicrobial
Susceptibility Testing [5]. The WT distribution is used to
deﬁne the ECOFF, which is the MIC of the upper part of this
distribution. The ECOFF is, by deﬁnition, devoid of pheno-
typically detectable acquired and mutational resistance
mechanisms to a certain drug, but should not be mixed up
with the clinical breakpoint [5].
We have previously shown a clear separation of susceptible
vs. resistant isolates based on ECOFFs for isoniazid and
rifampicin, which corresponds to clinical outcome and phar-
macokinetic and pharmacodynamic data [6]. In these studies we
used a high-throughput replicator method to test over 100
strains on solid media. This would be challenging in MGIT,
which is widely used for routine DST. Therefore, the aim was
to establish WT MIC distributions in MGIT by testing a limited
number of strains and correlating these to the MICs of the same
strains previously obtained on 7H10 medium and to the results
of mathematical modelling.
To establish the WT distribution, consecutive clinical iso-
lates from 15 patients diagnosed by MGIT and Löwenstein-
Jensen culture, as well as routine PCR at the tuberculosis
laboratory at the Karolinska University Hospital, were
included. All isolates were subsequently conﬁrmed as unique
by restriction fragment length polymorphism analysis asious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 2. Differences in MIC dilution steps for Mycobacterium
tuberculosis drug susceptibility testing in BACTEC 960 MGIT
compared to Middlebrook 7H10 (n [ 19)
MIC dilution
stepsa
RIF
(n)
INH
(n)
EMB
(n)
AMI
(n)
CAP
(n)
OFL
(n)
LEV
(n)
−2 2 1 1 5 0 0 0
−1 10 12 10 7 0 4 1
0 5 6 4 6 12 11 9
1 2 0 4 1 7 3 8
2 0 0 0 0 0 1 1
RIF, rifampicin; INH, isoniazid; EMB, ethambutol; AMI, amikacin; CAP, capreomycin;
OFL, oﬂoxacin; LEV, levoﬂoxacin.
aThe numerical difference in twofold MIC dilution steps between the two methods
for the tested drugs of each individual isolate using Middlebrook 7H10 as a refer-
ence for BACTEC 960 MGIT was indicated. One dilution step (1) indicates that the
MIC level for MGIT was higher than 7H10, and consequently, that −1 dilution step
indicates that 7H10 was higher than MGIT, whereas 0 indicates no difference be-
tween the methods.
CMI Sturegård et al. Research Note 148.e6described [6]. The strains were kept in −70°C and sub-
cultured on Löwenstein-Jensen media. All isolates were sus-
ceptible to ﬁrst- and second-line drugs [6]. The stock
solutions of isoniazid (INH), rifampicin (RIF), ethambutol
(EMB), levoﬂoxacin (LEV), oﬂoxacin (OFL), amikacin (AMI),
and capreomycin (CAP) were prepared as previously
described [6–8]. A 1:1 suspension from a positive MGIT
culture tube was inoculated in a fresh MGIT tube containing
antibiotics, and DST was subsequently performed according
to the manufacturer (BACTEC MGIT 960, Becton Dickinson,
Franklin Lakes, NJ, USA), including a 1:100 diluted control.
Serial twofold dilutions of the drugs were prepared and
MGIT tubes were inoculated in ﬁnal concentrations corre-
sponding to two MIC steps above and below the MICs that
had previously been obtained in the Middlebrook 7H10 [6–8].
In addition, for the ﬁrst-line drugs, the standard DST proce-
dure (SIRE-kit) was used [3]. M. tuberculosis H37Rv was
included in all experiments as an internal control. In addition,
MICs for all investigated antibiotics were determined for one
multi-drug-resistant (MDR)- and two INH-mono-resistant
strains.
For mathematical modelling, the normalised resistance
interpretation (NRI) method was applied, which utilizes the
fact that the lower part in an MIC distribution is not affected
by resistant isolates and the WT population can therefore be
mathematically reconstructed based on the shape of
this population [9]. The ECOFFs were deﬁned at 2.5 SD
above the calculated means. NRI was used with permission
from the patent holder, Bioscand AB, TÄBY, Sweden (Euro-
pean patent No 1383913) and performed as described pre-
viously [9].
In total, 735 MGIT tubes were used for the MIC determi-
nation of seven drugs including 15 WT isolates, three resistant
and one control isolate (Table 1). For the ﬁrst-line drugs, the
classiﬁcation into susceptible or resistant based on the MICTABLE 1. MIC distribution ranges (mg/L) in BACTEC 960 MGIT v
n
H37Rv H37Rv MDR MDR INH-R INH-R WT E
MGIT 7H10 MGIT 7H10 MGIT 7H10 MGIT M
3 9 1 1 2 2 15 1
INH 0.064 0.064–0.125 4 8 1;8 2;8 0.064–0.125 0
RIF 0.125–0.25 0.032–0.25 128 64 0.125/0.125 0.125;0.5 0.032–0.25 0
EMB 2–4 1–2 8 4 1;5 4;4 1.0–4.0 4
AMI 0.5 0.5–1 >512 >512 0.25;0.5 1;2 0.25–1.0 1
CAP 2 1–2 8 8 1;2 1;2 1.0–4.0 4
OFL 1 0.25–0.5 0.5 0.5 0.125;0.5 0.125;1 0.5–2.0 2
LEV 0.25–0.5 0.125–0.25 0.5 0.5 0.125;0.5 0.125;0.5 0.25–1.0 1
H37Rv, Mycobacterium tuberculosis strain H37Rv; MDR, multi-drug-resistant isolate; INH-R, is
off; NRI, normalised resistance interpretation; CC, critical concentration; INH, isoniazid; RIF,
levoﬂoxacin.
aDerived from [6].
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inshowed a perfect correlation to the SIRE-kit by the manufac-
turer. Further, the variation between and within runs for the
control strain (H37Rv) in three separate rounds never excee-
ded one MIC dilution step, indicating excellent reproducibility
(Table 1). The correlation between the individual MICs for
MGIT compared to 7H10 was perfect for 40% (53/133) of the
DSTs performed, and 91.7% were within ± one MIC dilution
step (Table 2). For LEV and CAP, MICs were 0.4–0.6 mean
dilution steps higher, whereas RIF and AMI were 0.75 MIC
dilution steps lower in MGIT compared to 7H10. A limitation of
the study is the few MIC determinations performed per drug
and thus, the suggested ECOFFs for MGIT need to be repeated
in other laboratories with a larger number of isolates. The
performance of the NRI analysis as an objective tool to
determine the ECOFF [9] was conﬁrmed by a close correlation
between the current critical concentrations and the proposed
ECOFFs within one MIC dilution step, except for RIF, which
was two MIC dilution steps lower (0.25 mg/L) compared to the
current critical concentration. This ﬁnding could partly explain
recent reports where RIF-susceptible strains exhibitedersus Middlebrook 7H10
COFF WT ECOFF ECOFF - NRI Mean ΔMIC 7H10 MGIT
GIT 7H10 7H10 2.5 SD MGIT 7H10 vs MGIT CC CC
5 15 90a 15 15
.125 0.032–0.064 0.125 0.14 0.063 0.2 0.1
.25 0.064–0.125 0.5 0.28 0.75 1 1
1.0–2.0 2 3.9 −0.25 5 5
0.5–1.0 1 1.12 0.75 ND 1
0.5–1.0 4 9.3 −0.44 10 2.5
0.5–1.0 1 2.8 −0.13 2 2
0.25–0.5 0.5 0.86 −0.56 2 2
oniazid monoresistant isolates; WT, wild-type; ECOFF, epidemiological wild-type cut-
rifampicin; EMB, ethambutol; AMI, amikacin; CAP, capreomycin; OFL, oﬂoxacin; LEV,
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 148.e5–148.e7
148.e7 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMImutations in rpoB [10]. Whether such isolates with MICs above
the tentative ECOFF (0.25 mg/L) but below the critical con-
centration (1 mg/L) carrying mutations in rpoB will respond to
standard doses of RIF is unknown and remains to be shown in
clinical trials. The MDR isolate was classiﬁed as susceptible for
EMB and CAP in 7H10 (4 mg/L and 8 mg/L, respectively) but
was resistant in the MGIT system (8 mg/L for both drugs) along
with conﬁrmed resistance mutations in the embB and rrs genes.
Thus, with the same MIC level, an isolate may be classiﬁed as
resistant or susceptible according to the current breakpoints,
indicating a poor reproducibility between methods and a risk of
misclassiﬁcation of clinical isolates.
In conclusion, we investigated the WT MIC distributions in
MGIT for ﬁrst- and second-line drugs, which corresponded well
to that of 7H10. We propose that WT MIC distributions for
M. tuberculosis are similar regardless of whether liquid or solid
Middlebrook media is used, and suggest that breakpoints could
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